{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:20:56Z","timestamp":1784647256811,"version":"3.55.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia & Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.clml.2024.01.001","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T08:42:32Z","timestamp":1705826552000},"page":"277-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["SOHO State of the Art Updates and Next Questions: Will CAR-T Replace ASCT in NDMM"],"prefix":"10.1016","volume":"24","author":[{"given":"Eric","family":"Jurgens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.clml.2024.01.001_bib0001","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","article-title":"Multiple myeloma: the (r) evolution of current therapy and a glance into future","volume":"105","author":"Annamaria","year":"2020","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.clml.2024.01.001_bib0002","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.clml.2024.01.001_bib0003","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.01.001_bib0004","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clml.2024.01.001_bib0005","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.01.001_bib0006","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"10297","key":"10.1016\/j.clml.2024.01.001_bib0007","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.clml.2024.01.001_bib0008","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2024.01.001_bib0009","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1182\/blood-2021-146060","article-title":"Updated results from CARTITUDE-1: phase 1b\/2 study of ciltacabtagene autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen receptor T cell therapy, in patients with relapsed\/refractory multiple myeloma","volume":"138","author":"Martin","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2024.01.001_bib0010","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.clml.2024.01.001_bib0011","doi-asserted-by":"crossref","first-page":"8016","DOI":"10.1200\/JCO.2021.39.15_suppl.8016","article-title":"Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: updated KarMMa results","volume":"39","author":"Anderson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.01.001_bib0012","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/fon-2021-1090","article-title":"Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma","volume":"18","author":"Anderson","year":"2021","journal-title":"Future Oncol"},{"issue":"23","key":"10.1016\/j.clml.2024.01.001_bib0013","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1002\/cncr.33171","article-title":"Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma","volume":"126","author":"Munshi","year":"2020","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.clml.2024.01.001_bib0014","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.01.001_bib0015","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/bmt.2014.226","article-title":"Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure","volume":"50","author":"St Bernard","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.clml.2024.01.001_bib0016","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/sj.leu.2401819","article-title":"Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure","volume":"14","author":"Tosi","year":"2000","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2024.01.001_bib0017","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/s41409-022-01657-y","article-title":"Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option","volume":"57","author":"Lazana","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2024.01.001_bib0018","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0609.2005.00446.x","article-title":"Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure","volume":"75","author":"Knudsen","year":"2005","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.01.001_bib0019","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1186\/s12885-018-4926-0","article-title":"Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study","volume":"18","author":"Antlanger","year":"2018","journal-title":"BMC Cancer"},{"issue":"14","key":"10.1016\/j.clml.2024.01.001_bib0020","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.clml.2024.01.001_bib0021","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2024.01.001_bib0022","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"10192","key":"10.1016\/j.clml.2024.01.001_bib0023","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"The Lancet"},{"issue":"10","key":"10.1016\/j.clml.2024.01.001_bib0024","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.clml.2024.01.001_bib0025","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.clml.2024.01.001_bib0026","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2024.01.001_bib0027","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2024.01.001_bib0028","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clml.2024.01.001_bib0029","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2024.01.001_bib0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-134538","article-title":"Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2024.01.001_bib0031","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.bbmt.2018.04.007","article-title":"Analysis of clinical factors and outcomes associated with nonuse of collected peripheral blood stem cells for autologous stem cell transplants in transplant-eligible patients with multiple myeloma","volume":"24","author":"Kansagra","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.clml.2024.01.001_bib0032","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JOP.19.00335","article-title":"Autologous stem-cell transplantation for multiple myeloma in the era of novel therapies","volume":"16","author":"Parrondo","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"10.1016\/j.clml.2024.01.001_bib0033","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN Guidelines\u00ae Insights: multiple Myeloma, Version 3.2022: featured Updates to the NCCN Guidelines","volume":"20","author":"Callander","year":"2022","journal-title":"J Natl Comprehensive Cancer Network"},{"issue":"12","key":"10.1016\/j.clml.2024.01.001_bib0034","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.3324\/haematol.2021.279179","article-title":"Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma","volume":"106","author":"Srour","year":"2021","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.clml.2024.01.001_bib0035","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/jcm10091841","article-title":"Treatment of multiple myeloma and the role of melphalan in the era of modern therapies-current research and clinical approaches","volume":"10","author":"Poczta","year":"2021","journal-title":"J Clin Med"},{"issue":"Suppl_1","key":"10.1016\/j.clml.2024.01.001_bib0036","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1182\/blood-2019-131472","article-title":"In-hospital complications and outcomes of autologous stem cell transplantation in multiple myeloma patients older than 65-years old in the United States: National Inpatient Sample Analysis, 2011-2015","volume":"134","author":"Bakalov","year":"2019","journal-title":"Blood"},{"issue":"Suppl_1","key":"10.1016\/j.clml.2024.01.001_bib0037","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1182\/blood-2019-131622","article-title":"Inpatient hospitalization's associated cost and mortality for myeloma patients undergoing autologous stem cell transplant: a 13-year analysis of the national inpatient sample","volume":"134","author":"Abbasi","year":"2019","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2024.01.001_bib0038","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1182\/blood.V124.21.3978.3978","article-title":"Utilization trend and in-hospital complications of autologous hematopoietic stem cell transplantation in multiple myeloma in the United States: 13 years perspective","volume":"124","author":"Savani","year":"2014","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.01.001_bib0039","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2020-142527","article-title":"Feasibility of outpatient autologous stem cell transplantation in multiple myeloma and risk factors predicting hospital admission","volume":"136","author":"Larsen","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.01.001_bib0040","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","volume":"28","author":"Musto","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.01.001_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101144","article-title":"Second malignancies in multiple myeloma; emerging patterns and future directions","volume":"33","author":"Maclachlan","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"issue":"15","key":"10.1016\/j.clml.2024.01.001_bib0042","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2011-05-355743","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)","volume":"118","author":"Mailankody","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2024.01.001_bib0043","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3324\/haematol.2015.127548","article-title":"Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years","volume":"100","author":"Engelhardt","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.01.001_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100757","article-title":"Second primary malignancies in multiple myeloma: a review","volume":"46","author":"Poh","year":"2021","journal-title":"Blood Rev"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.01.001_bib0045","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1182\/blood-2021-153669","article-title":"Second primary malignancies among patients with multiple myeloma","volume":"138","author":"Cutshall","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2024.01.001_bib0046","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1182\/bloodadvances.2022009138","article-title":"Impact of second primary malignancy post\u2013autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis","volume":"7","author":"Ragon","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2024.01.001_bib0047","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nrc3185","article-title":"Balancing repair and tolerance of DNA damage caused by alkylating agents","volume":"12","author":"Fu","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.clml.2024.01.001_bib0048","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.chembiol.2013.04.007","article-title":"DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology","volume":"20","author":"Cheung-Ong","year":"2013","journal-title":"Chem Biol"},{"issue":"14","key":"10.1016\/j.clml.2024.01.001_bib0049","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood.2022017094","article-title":"High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma","volume":"141","author":"Samur","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.01.001_bib0050","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood-2007-06-097444","article-title":"Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989","volume":"111","author":"Barlogie","year":"2008","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2024.01.001_bib0051","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms","volume":"140","author":"Sperling","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.01.001_bib0052","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hon.2248","article-title":"Lenalidomide and secondary acute lymphoblastic leukemia: a case series","volume":"35","author":"Tan","year":"2017","journal-title":"Hematol Oncol"},{"issue":"13","key":"10.1016\/j.clml.2024.01.001_bib0053","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1182\/bloodadvances.2022009212","article-title":"Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal","volume":"7","author":"Geyer","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.clml.2024.01.001_bib0054","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1007\/s12325-022-02083-8","article-title":"Treatment regimens for transplant-ineligible patients with newly diagnosed multiple myeloma: a systematic literature review and network meta-analysis","volume":"39","author":"Facon","year":"2022","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.clml.2024.01.001_bib0055","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2024.01.001_bib0056","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proceed Natl Acad Sci"},{"issue":"7","key":"10.1016\/j.clml.2024.01.001_bib0057","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nature Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.clml.2024.01.001_bib0058","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","article-title":"The promise and potential pitfalls of chimeric antigen receptors","volume":"21","author":"Sadelain","year":"2009","journal-title":"Curr Opin Immunol"},{"issue":"26","key":"10.1016\/j.clml.2024.01.001_bib0059","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2024.01.001_bib0060","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.01.001_bib0061","first-page":"92","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol Therap"},{"issue":"5","key":"10.1016\/j.clml.2024.01.001_bib0062","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"10.1016\/j.clml.2024.01.001_bib0063","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1182\/blood.V126.23.184.184","article-title":"Anti-CD19 chimeric antigen receptor-modified T cell therapy for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia: fludarabine and cyclophosphamide lymphodepletion improves in vivo expansion and persistence of CAR-T cells and clinical outcomes","volume":"126","author":"Turtle","year":"2015","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2024.01.001_bib0064","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2024.01.001_bib0065","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric antigen receptor T-cell therapies: barriers and solutions to access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"4","key":"10.1016\/j.clml.2024.01.001_bib0066","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11899-021-00635-3","article-title":"Balancing quality, cost, and access during delivery of newer cellular and immunotherapy treatments","volume":"16","author":"Geethakumari","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"issue":"11","key":"10.1016\/j.clml.2024.01.001_bib0067","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/intimm\/10.11.1693","article-title":"The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily","volume":"10","author":"Madry","year":"1998","journal-title":"Int. Immunol."},{"issue":"25","key":"10.1016\/j.clml.2024.01.001_bib0068","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2024.01.001_bib0069","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.clml.2024.01.001_bib0070","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.01.001_bib0071","article-title":"Ciltacabtagene autoleucel: the second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","volume":"13","author":"Abebe","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.clml.2024.01.001_bib0072","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.01.001_bib0073","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: more room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2024.01.001_bib0074","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.01.001_bib0075","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2024.01.001_bib0076","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2021-150519","article-title":"Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from magnetismm-1","volume":"138","author":"Sebag","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2024.01.001_bib0077","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2024.01.001_bib0078","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.01.001_bib0079","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1182\/blood-2021-146074","article-title":"CARTITUDE-2: efficacy and safety of ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy, in patients with multiple myeloma and early relapse after initial therapy","volume":"138","author":"Van de Donk","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.01.001_bib0080","unstructured":"Legend Biotech. Legend Biotech announces submission of supplemental application to the U.S. FDA for Expanded Use of CARVYKTI\u00ae (ciltacabtagene autoleucel). 2023. https:\/\/legendbiotech.com\/legend-news\/legend-biotech-announces-submission-of-supplemental-application-to-the-u-s-fda-for-expanded-use-of-carvykti-ciltacabtagene-autoleucel-2\/."},{"issue":"1","key":"10.1016\/j.clml.2024.01.001_bib0081","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2024.01.001_bib0082","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.clml.2024.01.001_bib0083","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"issue":"19","key":"10.1016\/j.clml.2024.01.001_bib0084","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","article-title":"Single- and double-hit events in genes encoding immune targets before and after T cell\u2013engaging antibody therapy in MM","volume":"5","author":"Truger","year":"2021","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.01.001_bib0085","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1182\/blood-2022-167602","article-title":"Role of TNFRSF17 and GPRC5D structural and point mutations in resistance to targeted immunotherapies in multiple myeloma (MM)","volume":"140","author":"Lee","year":"2022","journal-title":"Blood"},{"issue":"485","key":"10.1016\/j.clml.2024.01.001_bib0086","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.clml.2024.01.001_bib0087","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"10.1016\/j.clml.2024.01.001_bib0088","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1179\/1607845413Y.0000000079","article-title":"GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells","volume":"18","author":"Cohen","year":"2013","journal-title":"Hematology"},{"issue":"24","key":"10.1016\/j.clml.2024.01.001_bib0089","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.clml.2024.01.001_bib0090","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Schinke","year":"2023","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clml.2024.01.001_bib0091","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2024.01.001_bib0092","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2024.01.001_bib0093","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2024.01.001_bib0094","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"S1","key":"10.1016\/j.clml.2024.01.001_bib0095","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.01.001_bib0096","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41409-022-01664-z","article-title":"Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center","volume":"57","author":"Borogovac","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2024.01.001_bib0097","unstructured":"National Cancer Institute. Carvykti approval marks second CAR T-cell therapy for multiple myeloma. 2022. https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2022\/fda-carvykti-multiple-myeloma. Accessed January 31, 2024."},{"key":"10.1016\/j.clml.2024.01.001_bib0098","unstructured":"National Cancer Institute. FDA approves BCMA-targeted CAR T-cell therapy for multiple myeloma. 2021. https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2021\/fda-ide-cel-car-t-multiple-myeloma. Accessed January 31, 2024."},{"issue":"15_suppl","key":"10.1016\/j.clml.2024.01.001_bib0099","doi-asserted-by":"crossref","first-page":"TPS8053","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8053","article-title":"KarMMa-4: idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma","volume":"39","author":"Usmani","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2024.01.001_bib0100","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2021-146210","volume":"138","author":"Dytfeld","year":"2021","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024000181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024000181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T02:27:51Z","timestamp":1713925671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024000181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2152265024000181"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.01.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions: Will CAR-T Replace ASCT in NDMM","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}